Asthma

AAFA Statement in Response to AstraZeneca Asthma Inhaler Cost Announcement

Retrieved on: 
Monday, March 18, 2024
AAFA, Conditional sentence, AstraZeneca, White, Patient, Research, Asthma, Ecosystem, Access, Death, Government, Human, Medicine, Pharmaceutical industry

Washington, DC, March 18, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) welcomes efforts to make asthma medicines more affordable and accessible.

Key Points: 
  • Washington, DC, March 18, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) welcomes efforts to make asthma medicines more affordable and accessible.
  • AAFA continues to lead advocacy efforts to change the drug pricing ecosystem on behalf of the 27 million people in the United States with asthma.
  • "AAFA applauds AstraZeneca’s announcement to cap costs of asthma inhalers and urges other manufacturers to take similar steps to make medications more affordable and accessible,” said AAFA President and CEO Kenneth Mendez.
  • AAFA’s research indicates that when the cost of medicine becomes a barrier to treatment , people with asthma resort to rationing or simply discontinue use.

Report: Climate Change Makes Living with Allergies a Challenge

Retrieved on: 
Thursday, March 14, 2024
AAFA, Climate change, Season, Post-nasal drip, Asthma, City, Pollen, Allergy, Air pollution, Allergen, Conditional sentence, Hospital, Cochineal

The top 20 Allergy Capitals™ for 2024 are:

Key Points: 
  • The top 20 Allergy Capitals™ for 2024 are:
    This year’s report again calls attention to the urgency of the climate crisis.
  • Due to climate change, growing seasons start earlier and last longer than they did just 30 years ago.
  • “Climate change fuels a perfect storm of conditions that make allergy season worse for people with pollen allergy,” said AAFA President and CEO Kenneth Mendez.
  • “Allergies are a common asthma trigger and lead to increased hospital visits for asthma during peak pollen seasons.”
    For information on preventing and treating allergies and asthma, visit aafa.org .

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Retrieved on: 
Tuesday, March 12, 2024
BofA Securities, Montgomery Street, Exercise, Madison Avenue, Atopic dermatitis, Goldman Sachs, Telephone, SAN, Chronic obstructive pulmonary disease, Sale, Attention, Security (finance), Lexington Avenue, Asthma, Suite, Apsis, Prospectus, Therapy, Jefferies, Jefferies Group

The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.

Key Points: 
  • The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.
  • All of the shares were offered by Apogee.
  • Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel acted as joint book-running managers for the offering.
  • Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on March 7, 2024.

RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 12, 2024
Letter, Atopic dermatitis, Telephone, RAPT, News, Asthma, P.C, Therapy, FDA, Food

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT) on behalf of RAPT stockholders.

Key Points: 
  • NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against RAPT Therapeutics, Inc. (“RAPT” or the “Company”) (NASDAQ: RAPT) on behalf of RAPT stockholders.
  • Our investigation concerns whether RAPT has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • The company expects to receive a formal clinical hold letter from the FDA.”
    On this news, the Company’s stock price declined.

Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team

Retrieved on: 
Tuesday, April 2, 2024
Professional Services, Health, Human Resources, Clinical Trials, Pharmaceutical, Biotechnology, Polyp (medicine), Organization, University, Internal medicine, Growth, UCSF, Immunotherapy, CFO, Critical Care Medicine (journal), Business, Inflammation, Patient, Roche, TSLP, Acquisition, Bryant University, MD, Senior, MBA, Biology, Asthma, Therapy, Ithaca College, National Jewish Health, Sinusitis, Eli Lilly and Company, Genzyme, Ironwood Pharmaceuticals, Babson College, Management

Upstream Bio , a clinical-stage biotech company advancing verekitug (UPB-101) for respiratory disorders, today announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing verekitug (UPB-101) for respiratory disorders, today announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.
  • “I am thrilled to join Upstream Bio as CEO.
  • By evolving and building our leadership team with these additions, we are further positioning Upstream Bio to become a leader in the immunotherapy landscape.
  • I am pleased to welcome Rand, Mike and Lisa to the Upstream Bio team.”
    Dr. Sutherland joins Upstream Bio with more than 25 years of business and clinical experience, having most recently served as CEO of Seeker Biologics, and before that as President of Translate Bio prior to its acquisition by Sanofi.

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Retrieved on: 
Monday, April 1, 2024
Research, Biotechnology, Other Health, Health, Cosmetics, Pharmaceutical, Retail, Science, Oncology, Dermatology, Vitiligo, Prurigo nodularis, Patient, Collaboration, Asthma, JAK1, HS, Hidradenitis suppurativa, PN, CMS, Autoimmunity, Pharmaceutical industry

Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.

Key Points: 
  • Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.
  • Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
  • CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
  • “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

Retrieved on: 
Monday, April 1, 2024
Other Health, Research, Professional Services, Pharmaceutical, Medical Devices, Clinical Trials, Science, Biotechnology, Medical Supplies, Finance, Other Science, Health, TEVA, U.S. FDA, MDPI, Fluticasone, Patient, Doctor of Philosophy, MD, Asthma, Therapy, Teva, Pharmaceutical industry

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248).

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248).
  • As part of the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, will have the lead role in the operational execution and management of the planned clinical trials, focused on accelerating Teva’s ICS-SABA (TEV-‘248) clinical research program.
  • Teva will recognize the funding as a reduction in research and development expenses and will retain full rights to the Company’s ICS/SABA program.
  • “Bridging together Teva's deep therapeutic expertise with Launch Therapeutics' profound clinical and operational expertise generates value to execute and accelerate this program.

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

Scene Health and CareFirst Expand Partnership for Medicaid Members

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Professional Services, Managed Care, Other Health, Health, General Health, Pharmaceutical, Health Insurance, Infectious Diseases, Insurance, Clinical Trials, Culture, Johns Hopkins, Entrepreneurship, Partnership, CareFirst BlueCross BlueShield, Patient, Prescription, Asthma, Quality, Medicaid, Multimedia, Medicine, Hypertension, Pharmaceutical industry

Scene Health (Scene) and CareFirst BlueCross BlueShield (CareFirst), one of the country’s largest not-for-profit healthcare organizations, are proud to announce the expansion of their partnership.

Key Points: 
  • Scene Health (Scene) and CareFirst BlueCross BlueShield (CareFirst), one of the country’s largest not-for-profit healthcare organizations, are proud to announce the expansion of their partnership.
  • “Our partnership with Scene has helped deepen our understanding of the real-life experiences and challenges members were facing,” said Mike Rapach, President and CEO of CareFirst Community Health Plan Maryland (CHPMD).
  • “We are grateful for five years of outstanding partnership with CareFirst BlueCross BlueShield of Maryland’s Medicaid team.
  • “Innovations such as Scene Health's services seamlessly coordinated with other CareFirst health services, benefits, and rich network coverage are critical for us to improve the overall health and quality of care for our members."

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

Retrieved on: 
Monday, March 18, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Conference, Disease, Patient, LTP, Hereditary angioedema, HAE, Quality of life, Anxiety, University, KALV, Return, Treatment, Quality, Asthma, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.
  • “These data show once again that people living with HAE still face challenges in following established guidelines for treating their attacks,” said Ben Palleiko, Chief Executive Officer of KalVista.
  • “Even short treatment delays can lead to worse clinical outcomes, and despite efficacious on-demand treatments, the fact that they need to be injected results in barriers which lead to significant underuse and resultant overuse of long-term prophylaxis.
  • (Poster Presentation)
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users